<DOC>
	<DOC>NCT00475735</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy of an investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) when compared to placebo.</brief_summary>
	<brief_title>A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Patient is between 18 and 55 years of age (inclusive) Patient is an adult with a current DSMIV diagnosis of ADHD of inattentive or combined subtype, as assessed via a structured interview using the ACDS and AISRS Females of childbearing potential must use acceptable methods of birth control during the study and for 1 month posttherapy Patient has a history of a neurological disorder resulting in ongoing impairment Patient has a lifetime history of a psychotic disorder, bipolar disorder, or posttraumatic stress disorder Patient has evidence of ongoing depression Patient is sensitive or allergic to methylphenidate Patient has glaucoma Patient has a previous history of narrowing or blockage of the GI tract Patient has a history of a sleep disorder (e.g., insomnia, sleep apnea, nightmares, or night terrors) within 6 months prior to screening Patient has a history of a cardiovascular disorder within 6 months prior to screening Patient has moderate or severe persistent asthma Patient has a history of substance abuse or dependence not in sustained full remission for at least one year according to DSMIV Patient has taken part in a research study within the past 30 days of signing informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>